Pineal peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.
No pharmacopoeial monograph exists for this peptide, so quality rests on the supplier's internal specifications and on whatever independent testing a purchaser arranges. Certificates of analysis differ widely in which tests they report and in the limits applied. The counter-ion introduced during purification, commonly acetate or trifluoroacetate, changes the net peptide content of a given mass of powder, so two samples of equal weight may not contain equal amounts of the active sequence. Third-party laboratories can verify purity, identity, residual solvents, and counter-ion content for a fee, which makes documentation more informative than labelling.
Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Synthetic tetrapeptide, four residues |
| Nominal mass | Approximately 390 Da | Free peptide; salt forms differ |
| Appearance | White to off-white powder | Commonly supplied lyophilised |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffer |
| Typical storage | −20 °C, desiccated | Cold packs used during transport |
In its supplied form epitalon is a white to off-white powder, usually lyophilized and often hygroscopic. It dissolves readily in water and in aqueous buffers, and it is commonly handled as the acetate or trifluoroacetate salt to improve stability during purification and drying. The amide backbone is labile in aqueous media, so solutions are less durable than the dry solid. Handling notes in the chemical literature therefore emphasize keeping the powder dry, cool and shielded from light until it is dissolved.
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.
Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.
Regulatory treatment differs by country. No formulation of epitalon holds a marketing authorisation as a medicine in the United States or the European Union, where material sold for laboratory use is handled as a research chemical and is not intended for human consumption. In Russia, several short peptide preparations from the same institute's peptide series are registered medicinal products, and epitalon appears in that national context. Elsewhere it is frequently offered as a cosmetic ingredient, a category with lighter requirements. Advertising claims about longevity or disease prevention are restricted in most jurisdictions, which limits how sellers describe the compound.
Freeze-dried epitalon is normally kept at minus twenty degrees Celsius in a sealed, desiccated container, protected from light. Short excursions at ambient temperature during shipping are generally tolerated, but repeated warming and cooling cycles encourage moisture uptake, which shortens shelf life. Once dissolved, the peptide is far less stable than the solid: aqueous solutions are subject to hydrolysis and to deamidation at the aspartate and glutamate residues. Working solutions are therefore held refrigerated and used within days, and repeated freezing and thawing of the same vial is best avoided.
== Causes == It can occur in patients with severely compromised intestinal function, those undergoing total parenteral nutrition, those who have had gastrointestinal bypass surgery, and also in persons of advanced age (i.e., over 90). People dependent on food grown from selenium-deficient soil may be at risk for deficiency. Increased risk for developing various diseases has also been noted, even when certain individuals lack optimal amounts of selenium, but not enough to be classified as deficient. For some time now, it has been reported in the medical literature that a pattern of side effects possibly associated with cholesterol-lowering drugs (e.g., statins) may resemble the pathology of selenium deficiency.
== Function == EBP functions as a Δ8–Δ7 sterol isomerase, catalyzing the migration of the double bond in the sterol B-ring from the 8(9) to the 7(8) position. In the Bloch pathway of cholesterol biosynthesis, EBP converts zymosterol to dehydrolathosterol, while in the Kandutsch–Russell pathway it converts zymostenol to lathosterol.
Altered level of consciousness Neurologic signs including: blurred vision, headaches, focal seizures, myoclonic jerking, reversible paralysis Motor abnormalities including flaccidity, depressed reflexes, tremors or fasciculations Hyperviscosity and increased risk of blood clot formation Dehydration Weight loss Nausea, vomiting, and abdominal pain Weakness Low blood pressure with standing
The division mobilized to the Clermont area in Argonne, just west of Verdun, starting on 24 September, stationed there to act as a reserve for the US First Army. On 3 October, Major General George B. Duncan, commander of the 77th Division, relieved William Burnham of his duties and took over as commander of the 82nd. On the night of 6 October 1918, the 164th Brigade relieved troops of the 28th Division, which were holding the front line from south of Fléville to La Forge, along the eastern bank of the Aire River. On 7 October, the 82nd Division, minus the 163rd Brigade, which remained in reserve, attacked the northeastern edge of the Argonne Forest, taking "Hill 223" in the process. The division's right flank entered the commune of Cornay but later withdrew southeast. The division's left flank took the high ground northwest of Châtel-Chéhéry. On 9 October, the division's left flank advanced to form a line along the French pylons on the road to the Belgian city of la Louvière. Throughout October, the division advanced north-east along the Aire (Aisne) river. On 10 October, it relieved troops of the 1st Division in Ardennes at Fléville and Sommerance. The 82nd Division then relaunched an attack on Cornay and the Belgian city of Enghien, successfully re-establishing the front there. On 11 October, the right flank of the division took the high ground north of the Rance river while the left flank continued to advance along the Aire. The next day, the 42nd Division relieved the 82nd's troops in Sommerance.
Sources: en.wikipedia.org
{\displaystyle {\boldsymbol {\sigma }}=-p~{\boldsymbol {\mathit {I}}}+2~{\cfrac {\partial W}{\partial I_{1}}}~{\boldsymbol {B}}=-p~{\boldsymbol {\mathit {I}}}+{\cfrac {\mu J_{m}}{J_{m}-I_{1}+3}}~{\boldsymbol {B}}}
Diagnosis of soft-tissue sarcomas also begins with a thorough history and physical examination. Imaging studies can include either CT or MRI, although CT tends to be preferred for soft-tissue sarcomas located in the thorax, abdomen, or retroperitoneum. Positron emission tomography (PET) also may be useful in diagnosis, although its most common use is for staging (see below). As with bone sarcomas, definitive diagnosis requires biopsy of the tumor with evaluation of histology by a trained pathologist.
It is unlikely that chocolate consumption in small amounts causes lead poisoning. Some studies have shown that lead may bind to cocoa shells, and contamination may occur during the manufacturing process. One study showed the mean lead level in milk chocolate candy bars was 0.027 μg lead per gram of candy. Another study found that some chocolate purchased at U.S. supermarkets contained up to 0.965 μg per gram, close to the international (voluntary) standard limit for lead in cocoa powder or beans, which is 1 μg of lead per gram. In 2006, the U.S. FDA lowered by one-fifth the amount of lead permissible in candy, but compliance is only voluntary. Studies concluded that "children, who are big consumers of chocolates, may be at risk of exceeding the daily limit of lead, [as] one 10 g cube of dark chocolate may contain as much as 20% of the daily lead oral limit. Moreover chocolate may not be the only source of lead in their nutrition" and "chocolate might be a significant source of cadmium and lead ingestion, particularly for children." According to a 2005 study, the average lead concentration of cocoa beans is ≤ 0.5 ng/g, which is one of the lowest reported values for a natural food. However, during cultivation and production, chocolate may absorb lead from the environment (such as in atmospheric emissions of now unused leaded gasoline). The European Food Safety Authority recommended a tolerable weekly intake for cadmium of 2.5 micrograms per kg of body weight for Europeans, indicating that consuming chocolate products caused exposure of about 4% among all foods eaten.
Biological carbon fixation, or carbon assimilation, is the process by which living organisms convert inorganic carbon (particularly carbon dioxide, CO2) to organic compounds. These organic compounds are then used to store energy and as structures for other biomolecules. Carbon is primarily fixed through photosynthesis, but some organisms use chemosynthesis in the absence of sunlight. Chemosynthesis is carbon fixation driven by chemical energy rather than from sunlight. The process of biological carbon fixation plays a crucial role in the global carbon cycle, as it serves as the primary mechanism for removing CO2 from the atmosphere and incorporating it into living biomass. The primary production of organic compounds allows carbon to enter the biosphere. Carbon is considered essential for life as a base element for building organic compounds. The flow of carbon from the Earth's atmosphere, oceans and lithosphere into lifeforms and then back into the air, water and soil is one of the key biogeochemical cycles (or nutrient cycles). Understanding biological carbon fixation is essential for comprehending ecosystem dynamics, climate regulation, and the sustainability of life on Earth. Organisms that grow by fixing carbon, such as most plants and algae, are called autotrophs. These include photoautotrophs (which use sunlight) and lithoautotrophs (which use inorganic oxidation). Heterotrophs, such as animals and fungi, are not capable of carbon fixation but are able to grow by consuming the carbon fixed by autotrophs or other heterotrophs.
== Malignant neoplasm of digestive organs and peritoneum (150–159) == 150 Malignant neoplasm of esophagus 151 Malignant neoplasm of stomach 152 Malignant neoplasm of small intestine, including duodenum 153 Malignant neoplasm colon 154 Malignant neoplasm of rectum, rectosigmoid junction, and anus 155 Malignant neoplasm of liver and intrahepatic bile ducts 156 Malignant neoplasm of gallbladder and extrahepatic bile ducts 157 Malignant neoplasm of pancreas 158 Malignant neoplasm of retroperitoneum and peritoneum 159 Malignant neoplasm of other and ill-defined sites within the
Sources: en.wikipedia.org
Noninvasive imaging plays an important role in the diagnosis and characterisation of myocardial infarction. Tests such as chest X-rays can be used to explore and exclude alternate causes of a person's symptoms. Echocardiography may assist in modifying clinical suspicion of ongoing myocardial infarction in patients that can't be ruled out or ruled in following initial ECG and Troponin testing. Myocardial perfusion imaging has no role in the acute diagnostic algorithm; however, it can confirm a clinical suspicion of Chronic Coronary Syndrome when the patient's history, physical examination (including cardiac examination) ECG, and cardiac biomarkers suggest coronary artery disease. Echocardiography, an ultrasound scan of the heart, is able to visualize the heart, its size, shape, and any abnormal motion of the heart walls as they beat that may indicate a myocardial infarction. The flow of blood can be imaged, and contrast dyes may be given to improve image. Other scans using radioactive contrast include SPECT CT-scans using thallium, sestamibi (MIBI scans) or tetrofosmin; or a PET scan using Fludeoxyglucose or rubidium-82. These nuclear medicine scans can visualize the perfusion of heart muscle. SPECT may also be used to determine viability of tissue, and whether areas of ischemia are inducible.
The proposed explanation is that the sheer size of the sugar makes it hard for other molecules to interact with each other. In the American market, instant tea is expected by the consumer to be clear when reconstituted, which makes the cream an unacceptable part of the solution. Industrially, a variety of methods have been patented to deal with the issue, such as the utilization of tannase to solubilize the cream. Another method developed was based on the identification of two classes in cream: low molecular weight compounds such as the polyphenols that contribute to flavor, and higher molecular weight compounds such as polysaccharides, polypeptides, and proteins. This process removes the high molecular weight compounds through ultrafiltration, absorption chromatography or oil filtration. The flavor compounds remain and do not cream. After the extraction and tea creaming processes, the tea solution is still too dilute to pass through a drier. Drying at this point would take too much capital for little gain, and any type of spray or freeze-drying would cause the resulting powder to have too low a density. The answer is to first concentrate the solution to what is usually 40% solids before drying, which involves the removal of water through evaporation. Concentration of tea is normally done through reduction of pressure. At high temperatures, the theaflavins in the solution are converted to thearubigins and carbohydrates caramelize. Forced evaporation systems had hot spots which led to undesirable sensory characteristics such as stewed and burnt flavors.
Rinck PA (ed.). "MRI: A Peer-Reviewed, Critical Introduction". European Magnetic Resonance Forum (EMRF)/The Round Table Foundation (TRTF). A Guided Tour of MRI: An introduction for laypeople National High Magnetic Field Laboratory The Basics of MRI. Underlying physics and technical aspects. Video: What to Expect During Your MRI Exam from the Institute for Magnetic Resonance Safety, Education, and Research (IMRSER) Royal Institution Lecture – MRI: A Window on the Human Body A Short History of Magnetic Resonance Imaging from a European Point of View How MRI works explained simply using diagrams Real-time MRI videos: Biomedizinische NMR Forschungs GmbH. Paul C. Lauterbur, Genesis of the MRI (Magnetic Resonance Imaging) notebook, September 1971 (all pages freely available for download in variety of formats from Science History Institute Digital Collections at digital.sciencehistory.org) Images showing early MRI scans and the development of the MRI scanner from the archives of University of Nottingham Manuscripts and Spcial Collections Archive collections relating to the development of MRI at the University of Nottingham, including the papers of Nobel Prize winner Sir Peter Mansfield
== Research == Although primarily known for the development of computational methods for predicting and designing the structures and functions of proteins, Baker maintains an active experimental biochemistry group. He has authored over 600 scientific papers. Baker's group developed the Rosetta algorithm for ab initio protein structure prediction, which has been extended into a tool for protein design, a distributed computing project called Rosetta@home, and the computer game Foldit. Baker served as the director of the Rosetta Commons, a consortium of labs and researchers that develop biomolecular structure prediction and design software. His group has regularly competed in the CASP structure prediction competition, specializing in ab initio methods, including both manually assisted and automated variants of the Rosetta protocol. Using artificial intelligence, his group has developed later a newer version of the program known as RoseTTAFold. Baker's group is also active in the field of protein design; they are noted for designing Top7, the first artificial protein with a novel fold. In 2017, Baker's Institute for Protein Design received over $11 million from Open Philanthropy, followed by an additional $3 million donation in 2021. In April 2019, Baker gave a TED talk titled "5 challenges we could solve by designing new proteins" at TED2019 in Vancouver, Canada.
== Structure == Cardiac alpha actin is a 42.0 kDa protein composed of 377 amino acids. Cardiac alpha actin is a filamentous protein extending from a complex mesh with cardiac alpha-actinin (ACTN2) at Z-lines towards the center of the sarcomere. Polymerization of globular actin (G-actin) leads to a structural filament (F-actin) in the form of a two-stranded helix. Each actin can bind to four others. The atomic structure of monomeric actin was solved by Kabsch et al., and closely thereafter this same group published the structure of the actin filament. Actins are highly conserved proteins; the alpha actins are found in muscle tissues and are a major constituent of the contractile apparatus. Cardiac (ACTC1) and skeletal (ACTA1) alpha actins differ by only four amino acids (Asp4Glu, Glu5Asp, Leu301Met, Ser360Thr; cardiac/skeletal). The actin monomer has two asymmetric domains; the larger inner domain comprised by sub-domains 3 and 4, and the smaller outer domain by sub-domains 1 and 2. Both the amino and carboxy-termini lie in sub-domain 1 of the outer domain.
Sources: en.wikipedia.org
No. Epithalamin is a heterogeneous peptide fraction obtained from pineal gland extract and contains many components. Epitalon is a single synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. Researchers synthesised the shorter peptide while attempting to identify active sequences within the extract.
No endogenous peptide with this exact sequence has been described as a circulating hormone or signalling molecule. The tetrapeptide was designed as a synthetic analogue based on fragments observed in pineal preparations. Any activity discussed in the literature therefore refers to administered material rather than to a natural pool of the compound.
It is not an approved medicine in major jurisdictions and does not appear in the major pharmacopoeias. Material is usually distributed as a research chemical or laboratory reagent. Such labelling places handling responsibility on the purchaser and does not indicate that a regulatory body has reviewed the substance.
Mass spectrometry provides the identity check, because the observed mass is compared with the theoretical mass of the AEDG sequence. Chromatography separates and quantifies impurities but does not by itself prove which peptide is present. The two techniques are normally used together.